{"title":"Alirocumab: an investigational treatment for hypercholesterolemia","authors":"K. Ray","doi":"10.2217/clp.14.56","DOIUrl":null,"url":null,"abstract":"Kausik Kumar Ray is visiting Professor of Cardiovascular Disease Prevention in the Division of Cardiovascular Sciences, University of London, London, UK. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, UK, his MD (2004) at the University of Sheffield, UK, a postdoctoral fellowship at Harvard Medical School, Massachusetts, USA, and finally an MPhil in Epidemiology (2007) from the University of Cambridge, UK. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Professor Ray is also a member of the British Cardiovascular Society. Professor Ray has been the national lead investigator, served on the committees or been Principal Investigator for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY and DECLARE TIMI 58. Professor Ray's research interests have focused on the prevention and red...","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"32 1","pages":"12 - 9"},"PeriodicalIF":0.0000,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.14.56","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Kausik Kumar Ray is visiting Professor of Cardiovascular Disease Prevention in the Division of Cardiovascular Sciences, University of London, London, UK. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, UK, his MD (2004) at the University of Sheffield, UK, a postdoctoral fellowship at Harvard Medical School, Massachusetts, USA, and finally an MPhil in Epidemiology (2007) from the University of Cambridge, UK. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Professor Ray is also a member of the British Cardiovascular Society. Professor Ray has been the national lead investigator, served on the committees or been Principal Investigator for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY and DECLARE TIMI 58. Professor Ray's research interests have focused on the prevention and red...
期刊介绍:
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.